James Cail, DO
Family Medicine · Oklahoma City, OKNPI 1669403085
Payments from drug & device makers
Across 183 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$429
- Johnson & Johnson$357
- Amgen$324
- Otsuka America Pharmaceutical, Inc.$306
- Boehringer Ingelheim$163
- Genentech USA, Inc.$160
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,002100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $429 |
| Johnson & Johnson | 26 | $357 |
| Amgen(2 entities) | 24 | $324 |
| Otsuka America Pharmaceutical, Inc. | 17 | $306 |
| Boehringer Ingelheim | 9 | $163 |
| Genentech USA, Inc. | 5 | $160 |
| Novo Nordisk | 9 | $126 |
| Corcept Therapeutics | 7 | $117 |
| Merck | 5 | $79 |
| Pfizer | 4 | $77 |
| Lilly USA, LLC | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Antares Pharma, Inc. | 3 | $50 |
| Bausch Health US, LLC | 3 | $45 |
| Eisai Inc. | 3 | $44 |
| Alkermes, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Stryker | 1 | $41 |
| AstraZeneca | 3 | $38 |
| Astellas Pharma US Inc | 3 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Exact Sciences | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| IBSA Pharma Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $28 |
| GSK | 2 | $28 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Shire North American Group Inc | 1 | $25 |
| Abbott | 1 | $24 |
| Indivior Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| QOL Medical, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$124
How this compares
$3,002 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $91,549 |
| Invega SustennaPaliperidone Palmitate | 23 | $76,469 |
| AristadaAripiprazole Lauroxil | 16 | $52,790 |
| RexultiBrexpiprazole | 23 | $34,446 |
| VraylarCariprazine Hcl | 21 | $30,545 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $14,133 |
| OzempicSemaglutide | 13 | $12,728 |
| JardianceEmpagliflozin | 17 | $11,446 |
| Lurasidone Hcl | 14 | $10,683 |
| Aripiprazole | 66 | $8,497 |
| Quetiapine Fumarate | 94 | $4,239 |
| Varenicline Tartrate | 11 | $3,857 |
| Ziprasidone Hcl | 12 | $3,318 |
| Buspirone Hcl | 100 | $2,897 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 78 | $2,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $36 | $91,54911 claims |
| Johnson & JohnsonInvega Sustenna | $357 | $76,46923 claims |
| Alkermes, Inc.Aristada | $43 | $52,79016 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $306 | $34,44623 claims |
| AbbVieVraylar | $429 | $30,54521 claims |
| GSKTrelegy Ellipta | $28 | $14,13324 claims |
| Novo NordiskOzempic | $126 | $12,72813 claims |
| Boehringer IngelheimJardiance | $163 | $11,44617 claims |
| Lilly USA, LLCOlanzapine | $74 | $1,38341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.